Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term telbivudine treatment in adults with chronic hepatitis B previously in Idenix telbivudine studies
2004-004274-87Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of telbivudine in Chronic Hepatitis B (CHB), sponsored by Novartis. Primary endpoints: Primary Efficacy Endpoint for Patients with Compensated Chronic Hepatitis B and Long-term safety of telbivudine. Started Aug 2005; status: completed.
02
Drugs
telbivudine
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2004-004274-87.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004274-87.